



NEWS RELEASE

Novation and Université de Montréal/CRCHUM to present at Target ALS Annual Meeting May 4-5, 2021

FOR IMMEDIATE RELEASE

April 30, 2021

Port Coquitlam, Canada: Novation Pharmaceuticals Inc. announced today that Dr. Dominique Cheneval will be presenting with the Université de Montréal/CRCHUM's Drs. Christine Vande Velde and Alex Parker promising results from their collaboration at the virtual Target ALS Annual Meeting to be held May 4-5, 2021.

Dominique Cheneval, Novation CEO, will report on the exciting findings in the use of Novation's ALS *Quest* assay for the identification of small molecule regulators of G3BP1. Novation has developed a drug discovery approach to target the messenger RNA (mRNA) for G3BP1, a key player in the stress granule response, with small molecules as a therapy for ALS and FTD.

Drs. Vande Velde and Parker will present promising functional data for the selective compound hits identified by Novation's ALS *Quest* assay. Dr. Vande Velde's work has shown that altered regulation of the G3BP1 transcript, via its translation and stability, plays a key role in neurodegenerative disorders, such as ALS and FTD. Dr. Parker has developed an *in vivo* model in *C. elegans*, as a functional read-out for G3BP1 restoration.

About Novation and the *Quest* Technology

Novation is a product-focused company using *Quest*, its breakthrough drug-discovery technology that harnesses the natural cellular control function of mRNA modulation, to identify new therapeutics for a broad range of diseases, including neurodegeneration. *Quest* uses cell-based assays to identify small molecules that impact protein expression via mRNA modulation.

The ability to affect mRNA function with small molecular weight compounds opens up a wide range of disease areas to therapeutic intervention, including "non-drugable" targets, and to diseases currently treated with biologicals. A non-biased approach, *Quest* can identify both inhibitory and stimulatory small molecule compounds that modulate the stability of a target mRNA or influence its translatability.

Novation's suite of *Quest* drug-discovery assays span a number of disease areas, including targets in oncology, inflammation, cardiometabolic, neurodegeneration, and dyslipidemia. Novation is also developing assays for COVID-19 and other areas where there is a great need for small molecule therapeutics.

This news release contains certain forward looking statements. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the inherent risks associated with drug research and development, difficulties or delays in development testing, changes in regulatory affairs, lack of therapeutic efficacy, unacceptable side-effects, the dependence on partners, the inability to raise sufficient finance, the appearance of competitors and other risks generally associated with the biopharmaceutical industry.

For further information contact:

Dominique Cheneval, Ph.D.
CEO and Co-Founder
Novation Pharmaceuticals Inc.
Unit 104 - 2071 Kingsway Avenue
Port Coquitlam, B.C., Canada V3C 6N2
Telephone: 604.552.0768
Email: dcheneval@novation-pharma.com
Web site: www.novation-pharma.com